Back to Journals » Open Access Journal of Contraception » Volume 1

Efficacy and acceptability of outpatient, single-visit, medical abortion up to 59 days of gestation

Authors Agarwal M

Published 24 November 2010 Volume 2010:1 Pages 135—138

DOI https://doi.org/10.2147/OAJC.S14444

Review by Single anonymous peer review

Peer reviewer comments 5



Manisha Agarwal
Department of Obstetrics and Gynecology, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry, India

Abstract: This study evaluated the efficacy and acceptability of medical abortion by a modified, single-visit treatment regimen for termination of early (up to 59 days) pregnancy. The study population included 160 women. They were vaginally administered misoprostol 600 mg six hours after oral administration of mifepristone 200 µg. Patients’ symptoms were evaluated by telephone, and they were counseled accordingly. Follow-up sonography was performed two weeks later. The reasons patients chose this method were to avoid hospitalization, preference for a natural and noninvasive method, and confidentiality (55%). Side effects were mainly mild abdominal cramps (45%) and prolonged bleeding (2.4%). The success rate of complete abortion was 98.12%, with 1.25% of these patients needing a second vaginal dose to complete the treatment. The single-visit medical abortion method is acceptable and efficacious for women in developing countries.

Keywords: medical abortion, mifepristone, misoprostol, administration, intravaginal

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.